TRADE POLICY | 2026-02-09
Section 232 Pharmaceutical Tariffs: 100 Percent Branded Drug Import Duty Threat, MFN Drug Pricing Agreements with Pfizer, Eli Lilly, and Novo Nordisk, Country-Level Trade Deals, and the Evolving Global Negotiation Landscape for California Life Sciences Industry — February 2026
Following President Trump's September 2025 announcement of a 100 percent tariff on branded and patented pharmaceutical imports under Section 232 authority, a series of Most Favored Nation pricing agreements with major drugmakers and country-level deals have created a complex tariff landscape affecting the $212 billion U.S. pharmaceutical import market.
By Anatolii Trembach, Esq. (California State Bar No. 349304; LL.M., USC Gould School of Law; admitted to the U.S. Court of International Trade), Trembach Law Firm, APC · Published
In April 2025, President Donald Trump issued an Executive Order initiating a Section 232 investigation into the pharmaceutical supply chain under the Trade Expansion Act of 1962, marking the first time in the statute's history that national security authority was directed at the pharmaceutical sector. The United States imports approximately $212 billion in pharmaceutical products annually, sourcing nearly 80 percent of its generic drug tablets and capsules from foreign manufacturers.
Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.
Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301